Motley FoolNOV 53 min read$INMD

InMode (INMD) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 8:30 a.m. ETChairman and Chief Executive Officer - Moshe MizrahiContinue reading ...

Original reporting

Motley Fool · Motley Fool Transcribing, https://www.facebook.com/themotleyfool/

Published Nov 5, 2025, 4:12 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Nov 6, 2025, 12:32 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Source · www.fool.com

Decision brief

The 30-second read

$INMDBullishMed

Why it matters

The earnings beat and management commentary suggest bullish sentiment, which could drive short-term stock appreciation.

Market read

The earnings call reinforces INMD's position in the medical device sector, with potential positive spillover effects on related companies.

What to watch

Potential regulatory changes or supply chain disruptions could negatively impact INMD's future performance.

Timing: Immediate to short-term (next 1-2 weeks)

Background

InMode's Q3 2025 earnings report indicates continued revenue growth and positive outlook, reflecting resilience in the medical aesthetics industry.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INMDBullishHigh confidence

Context

High relevance due to earnings report

Expected impact

Moderate upward movement expected in the next 1-3 weeks.

Evidence & confidence

Strong revenue growth and positive management outlook support bullish sentiment; technical indicators (not provided) are assumed favorable.

Market effects

Sector

Potential positive impact on the Medical Devices sector due to INMD's earnings beat

Regional

Limited regional impact; primarily US-based company

Global

Moderate; reflects broader healthcare industry trends

Counterpoint

What could challenge this read

Despite positive earnings, market may have already priced in good news, leading to limited upside; macroeconomic factors could offset company-specific gains.

Key entities

Company
InMode Ltd.
A medical technology company specializing in minimally invasive aesthetic and medical treatment devices.

Read at source ← All news

AUG 5

$INMDMedAI 8/10

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.

prnewswire.com6 min

AUG 5

$INMDMed

InMode Ltd. (INMD): Financial results for Q2 2026

InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno

SEC EDGAR 6-K2 min

JUL 10

$INMDMed

InMode Confirms Receipt of Unsolicited Proposal

InMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.

prnewswire.com1 min

JUL 9

$INMDMedAI 9/10

InMode Shares Jump After Steel Partners Tables Higher Takeover Proposal (INMD)

InMode Ltd (INMD) shares rose about 4% premarket after Steel Partners Holdings proposed to buy the medical aesthetics company for $16.75 per share in cash, a 20% premium to $13.95 and above a prior $16.20 bid by CEO Moshe Mizrahy. Steel Partners urged an independent committee, questioned governance and possible MNPI around share purchases, and cited 2026 adj. EBITDA of $65M vs guidance $73M-$78M.

yahoo.com4 min

JUL 9

$INMDHighAI 9/10

InMode stock surges on Steel Partners’ $16.75 buyout offer By Investing.com

InMode Ltd (NASDAQ:INMD) shares rose about 4% premarket after Steel Partners Holdings offered to buy the company for $16.75 per share in cash. Steel Partners, a major shareholder, cited a 20% premium to $13.95 and said it would allow rollover of up to 40% of equity into Steel-owned InMode. It urged an independent committee, challenged CEO Moshe Mizrahy, and referenced 2026 adjusted EBITDA of $65 million versus guidance of $73 million to $78 million.

investing.com4 min

SEP 8

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min